Who are Niagen Bioscience, Inc.'s main suppliers?

Niagen Bioscience, Inc. (NAGE) key suppliers include: QUEEN-S-UNIVERSITY-BELFAST, OPKO Health, Inc.. View the full supplier network at chainsifter.com/chain/NAGE.

Who are Niagen Bioscience, Inc.'s major customers?

Niagen Bioscience, Inc. (NAGE) key customers include: CHROMADEX-ASIA-LIMITED-ASIA-PACIFIC-SCIENTIFIC-I, CHROMADEX-ASIA-PACIFIC-VENTURES-LIMITED, CHROMADEX-INC-CHROMADEX-INTERNATIONAL-INC-CHROMA, DELAWARE-GENERAL-CORPORATION, ELYSIUM-HEALTH-INC and 7 more. View the full customer network at chainsifter.com/chain/NAGE.

What sector is Niagen Bioscience, Inc. in?

Niagen Bioscience, Inc. (NAGE) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Niagen Bioscience, Inc. (NAGE) Supply Chain: 16 Verified Relationships

2Suppliers

12Customers

2Debt Items

11Related Chains

Source-Backed Evidence Depth

Niagen Bioscience, Inc. (NAGE) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

17Total relationships

2Distinct source URLs

4High confidence

0.693Average confidence

2026-09-13Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Niagen Bioscience, Inc. Suppliers

Ticker	Name	Confidence	Evidence
QUEEN-S-UNIVERSITY-BELFAST	QUEEN-S-UNIVERSITY-BELFAST	92%	Under the Agreement, QUB assigned to the Company all of QUB's right, title, and interest in the patent rights previously jointly owned or licensed to the Company under the JOMA and the License Agreement.
OPK	OPKO Health, Inc.	72%	Reciprocal relationship from OPK graph: ence over the particular investee and whether the particular equity security has a readily determinable fair value. We have determined that our ownership in th…

Niagen Bioscience, Inc. Customers

Ticker	Name	Confidence	Evidence
CHROMADEX-ASIA-LIMITED-ASIA-PACIFIC-SCIENTIFIC-I	CHROMADEX-ASIA-LIMITED-ASIA-PACIFIC-SCIENTIFIC-I	62%	udited Condensed Consolidated Financial Statements. 5 Table of Contents Niagen Bioscience, Inc. and Subsidiaries Unaudited Condensed Consolidated Statements of Cash Flows (In thousands) Three Months …
CHROMADEX-ASIA-PACIFIC-VENTURES-LIMITED	CHROMADEX-ASIA-PACIFIC-VENTURES-LIMITED	62%	udited Condensed Consolidated Financial Statements. 5 Table of Contents Niagen Bioscience, Inc. and Subsidiaries Unaudited Condensed Consolidated Statements of Cash Flows (In thousands) Three Months …
CHROMADEX-INC-CHROMADEX-INTERNATIONAL-INC-CHROMA	CHROMADEX-INC-CHROMADEX-INTERNATIONAL-INC-CHROMA	62%	udited Condensed Consolidated Financial Statements. 5 Table of Contents Niagen Bioscience, Inc. and Subsidiaries Unaudited Condensed Consolidated Statements of Cash Flows (In thousands) Three Months …
DELAWARE-GENERAL-CORPORATION	DELAWARE-GENERAL-CORPORATION	62%	arket price of our common stock could fluctuate significantly in response to various factors and events, including, but not limited to: • our ability to develop and commercialize our products; • our …
ELYSIUM-HEALTH-INC	ELYSIUM-HEALTH-INC	62%	roduct recall could result in substantial and unexpected expenditures, which would reduce operating profit and cash flow. In addition, a product recall may require significant management attention. P…
ELYSIUM-HEALTH-LLC	ELYSIUM-HEALTH-LLC	62%	roduct recall could result in substantial and unexpected expenditures, which would reduce operating profit and cash flow. In addition, a product recall may require significant management attention. P…
NESTEC-LTD	NESTEC-LTD	62%	ter. Under the terms of the arrangement, the parties agreed to resolve previously withheld receivables totaling approximately $ 1.3 million, the full balance was received by the Company as of the end…
NIAGEN-BIOSCIENCE-INC-CHROMADEX-INC	NIAGEN-BIOSCIENCE-INC-CHROMADEX-INC	62%	ter. Under the terms of the arrangement, the parties agreed to resolve previously withheld receivables totaling approximately $ 1.3 million, the full balance was received by the Company as of the end…
ROTH-CAPITAL-PARTNERS-LLC	ROTH-CAPITAL-PARTNERS-LLC	62%	. If they do so again, we may be forced to respond by lowering our prices. This would reduce sales revenues and increase losses. Failure to anticipate and respond to price competition may also impact…
SHANGHAI-CO-LTD	SHANGHAI-CO-LTD	62%	udited Condensed Consolidated Financial Statements. 5 Table of Contents Niagen Bioscience, Inc. and Subsidiaries Unaudited Condensed Consolidated Statements of Cash Flows (In thousands) Three Months …
THORNE-HEALTHTECH-INC	THORNE-HEALTHTECH-INC	62%	ter. Under the terms of the arrangement, the parties agreed to resolve previously withheld receivables totaling approximately $ 1.3 million, the full balance was received by the Company as of the end…
THORNE-RESEARCH-INC	THORNE-RESEARCH-INC	62%	ter. Under the terms of the arrangement, the parties agreed to resolve previously withheld receivables totaling approximately $ 1.3 million, the full balance was received by the Company as of the end…

Niagen Bioscience, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
NAGE-DEBT	Debt stack $2.6M	90%	Market cache reports total debt of $2.6M.
NAGE-DEBT-11159	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2019-12-31.

Niagen Bioscience, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Niagen Bioscience, Inc..

Niagen Bioscience, Inc. Ownership

Holder	Name	Confidence	Evidence
NAGE-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC	VANGUARD CAPITAL MANAGEMENT LLC	90%	13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 147 tracked holders.

Niagen Bioscience, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
OPK	OPKO Health, Inc.	100.00	1	['supplier']
ONCO	Onconetix, Inc.	50.00	2
WGS	GeneDx Holdings Corp.	50.00	2
CAMP	CAMP4 THERAPEUTICS CORPORATION	50.00	2
NIMU	Non-Invasive Monitoring Systems, Inc.	50.00	2
ASND	Ascendis Pharma A/S	50.00	2
LLY	Eli Lilly and Company	50.00	2
PFE	Pfizer Inc.	50.00	2
XBIO	Xenetic Biosciences, Inc.	50.00	2
ELOX	Eloxx Pharmaceuticals, Inc.	50.00	2
WGSWW	GeneDx Holdings Corp.	50.00	2

Niagen Bioscience, Inc. Supply Chain